Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release

Journal of Clinical Psychiatry

Volumn 68, Issue 1, 2007, Pages 58-68

  Ferguson, James M ^a   Khan, Arif ^b   Mangano, Richard ^c   Entsuah, Richard ^c   Tzanis, Evan ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Northwest Clinical Research Center   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VENLAFAXINE;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ADULT; AGORAPHOBIA; ANOREXIA; ANXIETY; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; OPEN STUDY; OUTPATIENT CARE; PAIN; PANIC; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCREENING; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SWEATING; TREATMENT RESPONSE; TREMOR; XEROSTOMIA;

EID: 33846861743     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0108     Document Type: Article

References (68)

1. Davidson JR. Generalized anxiety and panic: common, costly, and challenging disorders and their pharmacologic management. CNS Spectr 2004;9:1-7
2. Pollack MH, Allgulander C, Bandelow B, et al. WCA recommendations for the long-term treatment of panic disorder. CNS Spectr 2003;8:17-30
3. Hirschfeld RM. Panic disorder: diagnosis, epidemiology, and clinical course. J Clin Psychiatry 1996;57(suppl 10):3-8
4. Ball SG, Otto MW, Pollack MH, et al. Predicting prospective episodes of depression in patients with panic disorder: a longitudinal study. J Consult Clin Psychol 1994;62:359-365
5. Klerman GL, Weissman MM, Ouellette R, et al. Panic attacks in the community: social morbidity and health care utilization. JAMA 1991;265:742-746
6. Stein MB, Tancer ME, Uhde TW. Major depression in patients with panic disorder: factors associated with course and recurrence. J Affect Disord 1990;19:287-296
7. Swinson RP, Cox BJ, Woszczyna CB. Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. CMAJ 1992;147:878-883
8. Cowley DS, Flick SN, Roy-Byrne PP. Long-term course and outcome in panic disorder: a naturalistic follow-up study. Anxiety 1996;2:13-21
9. Eaton WW, Kessler RC, Wittchen HU, et al. Panic and panic disorder in the United States. Am J Psychiatry 1994;151:413-420
10. Yonkers KA, Zlotnick C, Allsworth J, et al. Is the course of panic disorder the same in women and men? Am J Psychiatry 1998;155:596-602
11. Warshaw MG, Massion AO, Shea MT, et al. Predictors of remission in patients with panic with and without agoraphobia: prospective 5-year follow-up data. J Nerv Ment Dis 1997;185:517-519
12. Katschnig H, Amering M. The long-term course of panic disorder and its predictors. J Clin Psychopharmacol 1998;18:6S-11S
13. Regier DA, Narrow WE, Rae DS. The epidemiology of anxiety disorders: the Epidemiologic Catchment Area (ECA) experience. J Psychiatr Res 1990;24(suppl 2):3-14
14. Keller MB, Baker LA. The clinical course of panic disorder and depression. J Clin Psychiatry 1992;53(suppl):5-8
15. Toni C, Perugi G, Frare F, et al. A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Pharmacopsychiatry 2000;33:121-131
16. Simon NM, Safren SA, Otto MW, et al. Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder. J Affect Disord 2002;69:201-208
17. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964;17:397-408
18. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo: Cross-National Collaborative Panic Study, Second Phase Investigators. Br J Psychiatry 1992;160:191-202
19. Garakani H, Zitrin CM, Klein DF. Treatment of panic disorder with imipramine alone. Am J Psychiatry 1984;141:446-448
20. Gloger S, Grunhaus L, Birmacher B, et al. Treatment of spontaneous panic attacks with clomipramine. Am J Psychiatry 1981;138:1215-1217
21. Cassano GB, Petracca A, Perugi G, et al. Clomipramine for panic disorder, 1: the first 10 weeks of a long-term comparison with imipramine. J Affect Disord 1988;14:123-127
22. Sasson Y, Iancu I, Fux M, et al. A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 1999;9:191-196
23. Mavissakalian M, Perel JM. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1992;49:318-323
24. Mavissakalian MR, Perel JM. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1999;56:821-827
25. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Panic Disorder. Am J Psychiatry 1998;155(suppl 5):1-34
26. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998;59:47-54
27. Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 1998;155:1570-1577
28. Michelson D, Allgulander C, Dantendorfer K, et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry 2001;179:514-518
29. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-379
30. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36-42
31. Lecrubier Y, Bakker A, Dunbar G, et al. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997;95:145-152
32. Pollack MH, Otto MW, Worthington JJ, et al. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998;55:1010-1016
33. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 1998;155:1189-1195
34. Londborg PD, Wolkow R, Smith WT, et al. Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998;173:54-60
35. Wade AG, Lepola U, Koponen HJ, et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997;170:549-553
36. Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005;187:352-359
37. Pollack MH, Lepola U, Koponen H, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2006 Aug 7 [Epub ahead of print]
38. Pollack M, Mangano RM, Entsuah R, et al. Short-term treatment of panic disorder: venlafaxine XR vs paroxetine or placebo. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga
39. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997;95:153-160
40. Lydiard RB, Steiner M, Burnham D, et al. Efficacy studies of paroxetine in panic disorder. Psychopharmacol Bull 1998;34:175-182
41. Michelson D, Pollack M, Lydiard RB, et al. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry 1999;174:213-218
42. Rapaport MH, Wolkow R, Rubin A, et al. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 2001;104:289-298
43. Lepola UM, Wade AG, Leinonen EV, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998;59:528-534
44. Versiani M, Cassano G, Perugi G, et al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002;63:31-37
45. Bertani A, Perna G, Migliarese G, et al. Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2004;37:206-210
46. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171-181
47. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999;60:22-28
48. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001;179:15-22
49. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 2000;283:3082-3088
50. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000;157:968-974
51. Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004;19:387-396
52. Liebowitz MR, Mangano RM. Venlafaxine XR in generalized social anxiety disorder. Presented at the 111th Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002; Montreal, Quebec, Canada
53. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine vs paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005;62:190-198
54. Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005;66:238-247
55. Rickels K, Mangano R, Khan A. Double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004;24:488-496
56. Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001;62:523-529
57. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville. Md: National Institute of Mental Health; 1976:218-222
58. Lipman RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 1982;18:69-77
59. Montgomery SA, Asberg MC. A new depression rating scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
60. Shear MK, Rucci P, Williams J, et al. Reliability and validity of the Panic Disorder Severity Scale: replication and extension. J Psychiatr Res 2001;35:293-296
61. Sheehan DV. The Anxiety Disease. New York, NY: Charles Scribner's Sons; 1983
62. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
63. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-326
64. Effexor [prescribing information]. Philadelphia, Pa: Wyeth Pharmaceuticals; 2006
65. Gorman JM, Liebowitz MR, Fyer AJ, et al. A neuroanatomical hypothesis for panic disorder. Am J Psychiatry 1989;146:148-161
66. Johnson MR, Lydiard RB, Ballenger JC. Panic disorder: pathophysiology and drug treatment. Drugs 1995;49:328-344
67. Coplan JD, Lydiard RB. Brain circuits in panic disorder. Biol Psychiatry 1998;44:1264-1276
68. Gorman JM, Kent JM, Sullivan GM, et al. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505